BioCentury
ARTICLE | Company News

BMS's NASH portfolio grows via deal for Nitto's siRNA

November 10, 2016 11:49 PM UTC

Nitto Denko Corp. (Tokyo:6988) granted Bristol-Myers Squibb Co. (NYSE:BMY) an exclusive, worldwide license to clinical candidate ND-L02-s0201 to treat liver diseases including non-alcoholic steatohepatitis (NASH). The companies' deal covers Nitto's molecules targeting serpin peptidase inhibitor clade H member 1, or heat shock protein 47 (SERPINH1; Hsp47), in vitamin A containing formulations.

Nitto will receive $100 million up front, and is eligible for undisclosed milestones, plus royalties...

BCIQ Target Profiles

Hsp47